Physician profile
Elliot M Levine
NPI 1669465233
$23,870.12
in general payments reported to CMS, 2019-2025
63 companies · $3,233 in 2025
The $3,233 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,973 · 2020: $2,722 · 2021: $3,412 · 2022: $3,593 · 2023: $4,043 · 2024: $3,895 · 2025: $3,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,125.85 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,788.78 | 2019-2025 | |
| Novo Nordisk INC | $2,590.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $2,472.90 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $2,379.19 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,760.03 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $1,406.35 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,081.02 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,023.03 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $693.24 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $627.16 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $618.35 | 2019-2025 | |
| Amgen INC. | $557.91 | 2019-2025 | Otezla, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $461.34 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $409.41 | 2020-2025 | Xifaxan |
| Amarin Pharma, INC. | $357.04 | 2019-2022 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.